The table below shows Axsome Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$93.41M
-$128.41M
-$145.08M
-$116.51M
-$108.23M
-$78.46M
Capital expenditure
$480.00K
$270.00K
$582.00K
$702.00K
$308.00K
$45.89K
Investing cash flow
-$480.00K
-$270.00K
-$582.00K
-$53.70M
-$308.00K
-$45.89K
Dividends paid
-
-
-
AXSM operating cash flow (10-K history)
Axsome Therapeutics, Inc. reported operating cash flow of -$93.41M for fiscal year 2025. That is up 27.3% from -$128.41M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$21.28M (FY 2016) to -$93.41M. Figures come from the company's audited annual reports as filed with the SEC.
